Use of transcription factors as agents and targets for drug development

ONCOLOGY

Volumn 10, Issue 10, 1996, Pages 1532-1538

  Smith, Leia M ^a   Birrer, Michael J ^b,c  

^a Biomarkers and Prev Research Branch   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; TRANSCRIPTION FACTOR;

CELL PROLIFERATION; DRUG DESIGN; DRUG DEVELOPMENT; DRUG TARGETING; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; MUTATION; ONCOGENE; PROTEIN DOMAIN; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL DIVISION; DNA, NEOPLASM; DRUG EVALUATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS; POINT MUTATION; TRANSCRIPTION FACTORS;

EID: 0029969116     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Radovick S, Nations M, Du Y, et al: A mutation in the POU-homoedomain of Pit-1 responsible for combined pituitary hormone deficiency. Science 257 1115-1118, 1992.
2. Spencer CA, Groudine M: Control of c-myc regulation in normal and neoplastic cells. Adv Cancer Res 56:1-48, 1991.
3. Hughes M, Rao BW: Genetic defects of receptors involved in disease, in Parker MG (ed): Nuclear Hormone Receptors: Molecular Mechanisms, Cellular Functions, Clinical Abnormalities, pp 321-353. London, Academic Press, 1991.
4. Papavassiliou A: Transcription factors: Structure, function, and implication in malignant growth. Anticancer Res 15:891-894, 1995.
5. Nimer SD: Transcription factors and malignancy, in Kurzrock R, Talpaz M (eds): Molecular Biology in Cancer Medicine, pp 113-128. London, Martín Dunitz, 1995.
6. Murre C, McCaw PS, Baltimore D: A new DNA binding and dimerization motif in immunoglobulin enhancer binding, daughterless, myoD, and myc proteins. Cell 56:777-783, 1989.
7. Landschulz WH, Johnson PF, McKnight SL: The leucine zipper. A hypothetical structure common to a new class of DNA binding proteins. Science 240:1759-1764, 1988.
8. Evans RM: The steroid and thyroid hormone receptor superfamily. Science 240:899-895, 1988.
9. Cooper GM: Pathways of Mitogenic signal-transduction, in Cooper GM: Oncogenes, pp 279-306 Boston, Jones and Bartlett, 1995.
10. Holt J: Fos and Jun: Inducible transcription factors regulating growth of normal and transformed cells, in Benz CC and Liu ET (eds): Oncogenes and Tumor Suppressor Genes in Human Malignancies, pp 301-311. Boston, Kluwer Academic, 1993.
11. Angel P, Karin M: The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biocheimica et Biophysica Acta 1072:129-157, 1991.
12. Chiu R, Angel P, Karin M: Jun-B differs in its biological properties from, and is a negative regulator of c-Jun. Cell 59:979-986, 1989.
13. Ryseck RP, Bravo R: c-JUN, JUN B, and JUN D differ in their binding affinities to AP-1 and CRE consensus sequences: Effect of FOS proteins. Oncogene 6:533-542, 1991.
14. Nakabeppu Y, Nathans D: A naturally occurring truncated form of fosb that inhibits fos/jun transcriptional activity. Cell 64:751-759, 1991.
15. Bravo R et al: Stimulation and inhibition of growth by EGF in different A431 cell clones is accompanied by the rapid induction of c-fos and c-myc proto-oncogenes. EMBO J 4:1193-1197, 1985.
16. Curran T, Bravo R, Muller R: Transient induction of c-fos and c-myc is an immediate consequence of growth factor stimulation. Cancer Surveys 4:655-681, 1985.
17. Buscher M et al: Activation of the c-fos gene by UV and phorbol ester: Different signal transduction pathways converge to the same enhancer element. Oncogene 3:301-311, 1988.
18. Lamph WW et al: Induction of proto-oncogene JUN/AP-1 by serum and TPA. Nature 334:629-631, 1988.
19. Szabo E, Brown PH, Birrer MJ, et al: The role of jun and fos gene family members in 12-O-tetradecanoylphorbol-13-acetate induced hemopoietic differentiation. Cell Growth Diff 2:475-482, 1991.
20. Herskowitz I: Functional inactivation of genes by dominant negative mutations. Science 329:219-222, 1987.
21. Espeseth AS, Darrow AL, Linney E: Signal transduction systems: Dominant negative strategies and mechanisms. Mol Cell Differentiation 1:111-161, 1993.
22. Alani R et al: The transactivating domain of the cJun Proto-oncoprotein is required for cotransformaiton of rat embryo cells. Mol Cell Biol 11:6286-6295, 1991.
23. Brown PH, Alani R, Preis LH, et al: Suppression of oncogene-induced transformation by a deletion mutant of c-jun. Oncogene 8:877-886, 1993.
24. Brown PH et al: "Dominant-negative" cJun mutants inhibit TPA/ras-induced transformation through multiple mechanisms. Proc Am Assoc Cancer Res 34:526, 1993.
25. Brown PH, Chen TK, Birrer MJ: Mechanism of action of a dominant-negative mutant of cJun. Oncogene 9:791-800, 1994.
26. Dong Z et al: Blocking of tumor promoter-induced AP-1 activity inhibits induced transformation in JB6 mouse epidermal cells. Proc Natl Acad Sci USA 91:609-613, 1994.
27. Rapp UR: Transformation by Raf and other oncogenes renders cells differentially sensitive to growth inhibition by a dominant negative cJun mutant. Oncogene 9:3493-3498, 1994.
28. Domann FE: Stable expression of a c-Jun deletion mutant in two malignant mouse epidermal cell lines blocks tumor formation in nude mice. Cell Growth Diff 5:9-16, 1994
29. Petrak D, Memon SA, Birrer MJ, et al: Dominant negative mutant of c-Jun inhibits NF-AT transcriptional activity and prevents IL-2 gene transcription. J Immunol 153:2046-2051, 1994.
30. Cippitelli M, Sica A, Viggiano V, et al: Negative transcriptional regulation of the interferon-g promoter by glucocorticoids and dominant negative mutants of c-Jun. J Biol Chem 270:12548-12556, 1995.
31. Benbrook DM, Jones NC: Heterodimer formation between CREB and JUN proteins. Oncogene 5:295-302, 1990.
32. Stein B, Baldwin AS Jr, Ballard DW, et al: Cross-coupling of the NFkB p65 and Fos/Jun transcription factors produces potentiated biological function. EMBO J 12:3879-3891, 1993.
33. Pfahl M: Nuclear receptors/AP-1 interaction. Endocr Rev 15:651-658, 1993.
34. Chen J-Y et al: RAR-specific agonist/antagonists which dissociate transactivation and AP-1 transrepression inhibit anchorage-independent cell proliferation. EMBO J 14:1187-1197, 1995
35. Fanjul A: A new class of retinoids with selective inhibition of AP-1 inhibits proliferation. Nature 372:107-111, 1994.
36. Elledge RM, Lee W-H. Life and death by p53. Bioessays 17:923-930, 1995.
37. Cho Y, Gorina S, Jeffrey PD, et al: Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations. Science 265:346-355, 1994.
38. Gjerset RA: Use of wild-type p53 to achieve complete treatment sensitization of tumor cells expressing endogenous mutant p53. Mol Carcinog 14:275-285, 1995.
39. Zhang W-W: High efficiency gene transfer and high level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus. Cancer Gene Ther 1:5-13, 1994.
40. Ranade K, Poteete AR: A switch in translation mediated by an antisense RNA. Genes Dev 7:1498-1507, 1993
41. Ikemoto H, Tani E, Matsumoto T, et al: Apoptosis of human glioma cells in response to calphostin C, a specific protein kinase C inhibitor. J Neurosurg 83:1008-1016, 1995.
42. Staal FJ, Roederer M, Herzenberg LA. Intracellular thiols regulate activation of nuclear factor kappa B and transcription of human immunodeficiency virus. Proc Natl Acad Sci USA 87:9943-9947, 1990.
43. Jin YJ, Burakoff SJ: The 25-kDa FK506-binding protein is localized in the nucleus and associates with casein kinase II and nucleolin. Proc Natl Acad Sci USA 90:7769-7773, 1993.
44. King IC, Feng M, Catino JJ: High throughput assay for inhibitors of the epidermal growth factor receptor-associated tyrosine kinase. Life Sci 53:1465-1472, 1993.
45. White JH, McCraig KA, Mader S: A simple and sensitive high-throughput assay for steroid agonists and antagonists. Biotechnology 12:1003-1007, 1994.